Hemoglobin A1c (A1c) and Liver Transplantation

What A1c Actually Measures

A1c is the percentage of hemoglobin in red blood cells that has glucose attached to it, reflecting average blood glucose over the life span of the red cell (roughly 2–3 months).[1–3,11]

• Higher blood sugar → more glucose sticks to hemoglobin → higher A1c.[1–3]
• The American Diabetes Association (ADA) uses A1c ≥6.5% to diagnose diabetes and often recommends a target A1c <7% for many non-pregnant adults, with individualization based on age, comorbidities, and hypoglycemia risk.[6,8,12,20,23]
• A1c is convenient because it does not require fasting and is not affected by short-term fluctuations in glucose on any single day.[6,8,12,23]

Why A1c Can Be Misleading in Advanced Liver Disease

In cirrhosis, A1c may underestimate—or occasionally overestimate—true average glucose because red-blood-cell survival and protein metabolism are abnormal.[1,3,7,10,11,12,15]

• Shortened red-cell survival from hypersplenism, anemia, or bleeding can lower A1c even when glucose is high.[1,3,10,11,15]
• Blood transfusions dilute the patient’s own red cells and may make A1c appear lower or higher depending on donor values and timing.[1,3,10,11]
• Iron deficiency, hemoglobin variants, and chronic kidney disease also distort A1c results, which is common in patients awaiting transplant.[10–12,15]
• Several studies in cirrhosis show that a substantial proportion of patients have A1c values in or below the “normal” range despite clearly abnormal glucose and elevated fructosamine or glycated albumin.[1,3,10,11,14]
• Newer indices such as CLD-HbA1c attempt to correct for altered red-cell life span, but they are not widely available and remain mainly research tools.[13]

Bottom line: in decompensated cirrhosis and portal hypertension, A1c is only one piece of the glycemic puzzle and should be interpreted alongside glucose logs, CGM tracings, and short-term markers such as fructosamine.[1,3,7,10–12,14,15]

Pre-Transplant A1c: Why It Still Matters

Even with its limitations, pre-transplant A1c offers useful information about long-term glucose exposure, self-management, and potential risk for complications or non-adherence.[2,6,7,10,14]

• Poorly controlled diabetes (for example A1c ≥9–10%) has been associated with higher cardiovascular risk, infections, and worse outcomes in major surgery and transplant.[2,6,7,10,14]
• Some transplant programs treat very high A1c as a “red flag” and use it to prompt additional diabetes education and psychosocial evaluation before listing.[2,6,14]
• Because A1c may underestimate glycemia in cirrhosis, a “reassuring” A1c (for example 6.0–6.5%) does not guarantee safe control if finger-stick or CGM readings show frequent or prolonged hyperglycemia.[1,3,7,10,11,14]
• Oral glucose tolerance testing (OGTT), fasting glucose, fructosamine or glycated albumin, and CGM can uncover “hidden” diabetes or marked post-meal glucose spikes not reflected in A1c alone.[1,3,4,7,11,14]

After Transplant: A1c and Post-Transplant Diabetes

After liver transplant, anemia and hypersplenism often improve, so A1c becomes more reliable; however, immunosuppressive drugs can cause or worsen “post-transplant diabetes mellitus” (PTDM).[2,5,7,9,13,14]

• Calcineurin inhibitors (especially tacrolimus), corticosteroids, and some other agents can impair insulin secretion and increase insulin resistance, predisposing to PTDM.[5,7,9,13]
• International consensus statements suggest A1c targets similar to other high-risk adults (often <7% if safely achievable), with less stringent goals (for example <7.5–8%) in older, frail, or hypoglycemia-prone transplant recipients.[5,6,8,9,12,20,21,23]
• Studies comparing pre- and post-transplant A1c show that values may rise after transplant as anemia resolves and red-cell lifespan normalizes—so a modest “jump” in A1c can partly reflect a more accurate measurement rather than a sudden deterioration in control.[2,9,13,14]
• Long-term PTDM is associated with higher cardiovascular events, infections, and kidney disease, underscoring the importance of early detection and active management.[5,7,9,13,18,21]

Beyond A1c: Complementary Tests in Liver Disease

In cirrhosis and the early post-transplant period, clinicians often use multiple markers—not just A1c—to judge glycemic control.[1,3,4,6,7,10–12,15]

• Capillary finger-stick monitoring (for example before meals and at bedtime) is a direct way to detect both hyper- and hypoglycemia, especially during medication titration or acute illness.[6,12,23]
• Continuous glucose monitoring (CGM) provides “time in range,” hypoglycemia burden, and trend data that are often more actionable than a single A1c value.[4,6,12]
• Fructosamine and glycated albumin reflect glycemia over roughly 2–3 weeks and can be helpful when A1c is clearly unreliable, although very low albumin can also confound these tests.[1,3,7,10,11,14,15]
• Corrected indices such as CLD-HbA1c have been proposed specifically for chronic liver disease, but they are not widely available and should be interpreted by experienced specialists.[13]
• For diagnosis of diabetes in cirrhosis, OGTT remains valuable because fasting glucose or A1c alone may miss isolated post-meal hyperglycemia.[1,3,7,11,14]

Practical Tips for Patients with Liver Disease and Diabetes

Treat A1c as a summary marker—not the whole story—especially if you have cirrhosis or are awaiting transplant.[1–3,6,7,10–12,14,15]

• Ask your team how trustworthy A1c is in your case (for example, “My hemoglobin and platelets are low—does that make my A1c less reliable?”).[1,3,10,11,15]
• Bring your meter or CGM download to each visit; if A1c looks “good” but many readings are high, talk about whether additional testing (fructosamine, glycated albumin, OGTT) is needed.[1,3,4,6,7,11,12,14]
• Before transplant, work with endocrinology to improve glucose patterns without provoking severe hypoglycemia; even modest A1c improvement combined with fewer extremes can reduce surgical risk.[2,6,7,10,14]
• After transplant, ask how often you should check glucose and A1c, especially when steroid or tacrolimus doses change.[5,7,9,13,18,21]
• Remember that diet, activity (as tolerated), weight management, and adherence to immunosuppressants all interact with blood sugar control and long-term graft health.[5,7,9,13,18,21]